Clinical TrialMay 27, 2026, 07:32 AM
Jupiter Neurosciences Begins Phase 2a Trial for JOTROL™ in Parkinson's Disease
AI Summary
Jupiter Neurosciences announced that patient enrollment has commenced for its Phase 2a RESET clinical trial (NCT07592767) evaluating JOTROL™ for Parkinson's Disease, with first patient dosing expected soon. JOTROL™ is an investigational oral candidate targeting underlying biological drivers of neurodegeneration in a market with no current disease-modifying therapies. The global Parkinson's Disease treatment market, valued at $5.65 billion in 2024, is projected to grow to $7.58 billion by 2030. The multi-center, randomized, double-blind, placebo-controlled study will enroll 30 patients, with completion anticipated in H1 2027.
Key Highlights
- Patient enrollment is underway for the Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ in Parkinson's Disease.
- The global Parkinson's Disease treatment market is valued at $5.65 billion in 2024, projected to reach $7.58 billion by 2030.
- The Phase 2a trial will enroll 30 patients (1:1:1 randomization) for a duration of 12 weeks.
- Study completion for the RESET trial is projected for H1 2027.
- FDA IND for JOTROL™ was cleared in November 2025, enabling the Phase 2a clinical evaluation.
- JOTROL™ demonstrated ~9-fold higher overall plasma bioavailability compared to conventional resveratrol in Phase 1.
- No serious adverse events were reported in the completed Phase 1 study (n=24 healthy volunteers).
Price Impact
More from JUNS